| ●Editorial | Nomoto M | 169 | Full text | |
| ●The 12th Setouchi International Conference on Clinical Trials / The 32nd Aso-Kujyu Conference on Clinical Pharmacology | 171-230 | Abstract | ||
| Organized by： Clinical Research Trial Center, Ehime University Hospital | ||||
| Opening remarks | Nomoto M | 174 | ||
| Accelerating regulatory science initiative | Miyata T | 175-82 | ||
| Clinical translation of hepatocyte growth factor for amyotrophic lateral sclerosis | Aoki M | 183-9 | ||
| Challenges in the academic institution | Moritoyo T | 190-7 | ||
| What can the Pharmaceutical Company do in the cooperation of industrial,
administrative and academic sectors in a clinical study? |
Iwasaki K | 198-204 | ||
| Collaboration between academia and pharma | Iwasaki M | 205-10 | ||
| General discussion | 211-4 | |||
| An introduction to Bayesian adaptive design | Lewis RJ | 215-29 | ||
| Closing remarks | Nomoto M | 230 | ||
| Adaptive designs in clinical trials: An overview | Origasa H | 231-40 | Abstract | |
| ●Medical Innovation Management and the trend of data standardization | ||||
| Medical Innovation Management: Principle and Practice | Fukushima M，editor． | 241-394 | Full text | |
| The comment on FDA draft guidances about regulatory submissions in electronic format-standardized study data | Jyouno T | 395-402 | Abstract | |
| Guidance for Industry: Providing Regulatory Submissions in Electronic
Format－ Standardized Study Data［draft guidance］ | FDA-CDER，CBER (trans. by Jyouno T) | 403-10 | ||
| ●World trend of ethics and science of clinical trial | ||||
| Interview with Dr. Robert Temple on drug evaluation policy of FDA | Temple R，et al． | 411-23 | Full text | |
| The WMA Council Session in Tokyo, 2014: Globalized medical ethics and research ethics | Mungherera M，et al． | 425-57 | Full text | |
| Challenges in regulating biomedical research: The Human Subjects Research Act and the Human Biobank Management Act in Taiwan | Chen I | 459-66 | Abstract | |
| Trend of research ethics and conflict of interest management in Korea and Taiwan | Kurihara C | 467-84 | Full text | |
| Reformation of clinical trial regulations in European Union (EU) | Kurihara C | 485-500 | Full text | |
| ●Instructions for authors［Japanese］＆［English］ | 501-9 | Full text | ||
| ●Editor’s note | Kawai S | 511 | Full text | |
| ［Electronic publications only］ | ||||
| ●Articles | ||||
| Publication denied: A case analysis of infringement of publication integrity and ethics | Matsui K，et al． | 513-7 | Full text | |
| Analyzing the development of ethics guidelines for nursing research in Japan | Matsui K，et al． | 519-30 | Full text | |
| ●Forum | ||||
| Open dialogue approach to acute psychosis | Saio T | 531-7 | Full text | |
| ●English versions of articles in Japanese | ||||
| Interview with Dr. Robert Temple on drug evaluation policy of FDA | Temple R，et al． | 539-51 | Full text | |
| The WMA Council Session in Tokyo, 2014 | Mungherera M，et al． | 553-90 | Full text | |
| Trend of research ethics and conflict of interest management in Korea and Taiwan | Kurihara C | 591-610 | Full text | |